On May 23, the FDA approved abiraterone acetate (Yonsa, Sun Pharmaceutical Industries Ltd.) in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Read the Sun Pharma press release here.
Posted 5/24/2018
In recognition of Leukemia and Lymphoma Awareness Month, ACCC compiled a group of resources to help care teams navigate two of the most commonly diagnosed adult leukemias: acute myeloid leukemia and chronic lymphocytic leukemia.
